r. Miccio’s main research interests are in transcriptional control of hematopoiesis and development of therapeutic approaches to hematologic genetic disorders. As a PhD student at TIGET (Telethon Institute) in Milan, she acquired scientific expertise in molecular biology and development of lentiviral (LV) vectors for genetic modification of different cell types, including hematopoietic stem cells (HSC) (Bonanomi, J Neurosci. 2005; Cattoglio, Blood, 2007; Felice, PlosOne, 2009). The strong background in hematology, which she acquired in Prof. Ferrari’s lab, allowed her to apply the LV technology to the field of gene therapy for β-thalassemia. She generated a β-globin expressing LV and demonstrated that transplantation of LV-transduced HSC is able to rescue the murine thalassemic phenotype (Miccio, PNAS, 2008). During her post-doctoral period in Philadelphia in Prof. Blobel’s lab, she acquired experience in epigenetics and regulation of gene expression in HSC and their differentiated progeny. Her projects were focused on transcriptional regulation by GATA1 and FOG1 hematopoietic transcription factors, and by the NuRD complex. She demonstrated that NuRD mediates activating and repressive functions of GATA1 and FOG1 during blood development and is required for FOG1-dependent activation of adult-type globin gene expression (Miccio, EMBO J, 2010; Miccio, MCB, 2010 and Gregory and Miccio, Blood, 2010). Upon the completion of her studies in Blobel’s lab, she took advantage of her experience in this excellent lab to develop new ideas in the laboratory of Fulvio Mavilio at the University of Modena (UNIMORE), Italy. In 2012 she was awarded the “Future in Research” grant from the Italian Ministry of Research and Education and she was appointed Assistant professor at UNIMORE. Here, she decided to combine her expertise in gene therapy, vector design, epigenetics and gene transcription to pursue her continued interests in hematopoiesis and hemoglobinopathies. Her work at UNIMORE aimed at achieving persistent and position-independent transgene expression in the context of human β-globin expressing LV (Miccio et al, PlosOne, 2012, Moiani et al., JCI, 2012). In 2013, she was recruited as a Lab Director at the Imagine Institute (Paris, France), where she pursued her studies on transcriptional regulation of gene expression in HSC and their myeloid and erythroid progeny (Romano et al., Scientific Reports; Poletti et al., PlosOne, 2015; Cavazza et al., Stem Cell Reports, 2016; Romano et al., JOVE, 2017). Currently, she is interested in studying the transcriptional regulation of the globin genes and the role of the hematopoietic nuclear factors in hemoglobin switching (Romano et a., in preparation). Her projects aim at developing novel genome editing-based strategies for β-thalassemias and Sickle Cell Disease ((Antoniani et al., Blood, 2018; Lagresle et al., Haematologica, 2018; Weber et al., MTMCD; Lattanzi et al., Mol Therapy, 2018).